Open Access
Refine
Document Type
- Article (146)
- Conference Proceeding (104)
- Report (19)
- Doctoral Thesis (10)
- Patent (1)
Is part of the Bibliography
- yes (280) (remove)
Keywords
Institute
Die Anforderungen an gute Unternehmensführung (Corporate Governance) nehmen in der Praxis stetig zu. Dies ist zum einen auf eine stark ansteigende Regulierungsdichte zurückzuführen. Beispiele wie die 2018 in Kraft tretende EU-Datenschutzgrundverordnung, das neue CSR-Richtlinie-Umsetzungsgesetz oder das seit 2016 anzuwendende Gesetz zur gleichberechtigen Teilhabe von Frauen in Führungspositionen zeigen, dass internationale und nationale Gesetzgeber das Thema Corporate Governance als außerordentlich wichtig erachten.
Speichereinsatz versus Netzausbau - Methoden der Bürgerkommunikation am Beispiel des Projekts NEOS
(2020)
Enterprise Architecture (EA) Frameworks (EAFs) have attempted to support comprehensive and cohesive modeling and documentation of the enterprise. However, these EAFs were not conceived for today’s rapidly digitalized enterprises and the associated IT complexity. A digitally-centric EAF is needed, freed from the past restrictive EAF paradigms and embracing the new potential in a data-centric world. This paper proposes an alternative EAF that is digital, holistic, and digitally sustainable - the Digital Diamond Framework. D2F is designed for responsive and agile enterprises, for aligning business plans and initiatives with the actual enterprise state, and addressing the needs of EA for digitized structure, order, modeling, and documentation. The feasibility of D2F is demonstrated with a prototype implementation of an EA tool that applies its principles, showing how the framework can be practically realized, while a case study based on ArchiSurance example and an initial performance and scalability characterization provide additional insights as to its viability.
Relevance and Adoption of AI technologies in German SMEs – Results from Survey-Based Research
(2021)
Preliminary study: Polishing force measurement by viscosity - the return of ketchup polishing
(2021)
Potentials of Digital Business Models – Empirical investigation of data driven impacts in industry
(2018)
Potential Benefits of Enterprise Architecture Management in the Digital Transformation Process
(2020)
Organizational Aspects of Cyber Security in Family Firms – an Empirical Study of German Companies
(2021)
Organische Chemie
(2021)
Optimierung der Oberflächengüte additiv gefertigter transmittierender Optiken mittels Dip-Coating
(2018)
One Single Click is enough – an Empirical Study on Human Threats in Family Firm Cyber Security
(2021)
On the road again: Wie kann die Arbeitsgestaltung zur Arbeitsfreude bei mobiler Arbeit beitragen?
(2020)
The over-expression and aggregation of α-synuclein (αSyn) are linked to the onset and pathology of Parkinson's disease. Native monomeric αSyn exists in an intrinsically disordered ensemble of interconverting conformations, which has made its therapeutic targeting by small molecules highly challenging. Nonetheless, here we successfully target the monomeric structural ensemble of αSyn and thereby identify novel drug-like small molecules that impact multiple pathogenic processes. Using a surface plasmon resonance high-throughput screen, in which monomeric αSyn is incubated with microchips arrayed with tethered compounds, we identified novel αSyn interacting drug-like compounds. Because these small molecules could impact a variety of αSyn forms present in the ensemble, we tested representative hits for impact on multiple αSyn malfunctions in vitro and in cells including aggregation and perturbation of vesicular dynamics. We thereby identified a compound that inhibits αSyn misfolding and is neuroprotective, multiple compounds that restore phagocytosis impaired by αSyn overexpression, and a compound blocking cellular transmission of αSyn. Our studies demonstrate that drug-like small molecules that interact with native αSyn can impact a variety of its pathological processes. Thus, targeting the intrinsically disordered ensemble of αSyn offers a unique approach to the development of small molecule research tools and therapeutics for Parkinson's disease.